COVID-19
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
On Tuesday, the U.K. offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications.
An in vitro study conducted by scientists from Northwestern University and Utah State University concluded COVID nasal spray as an effective medicine. Learn more here.
Regeneron announced positive initial data from its ongoing Phase III trial of its antibody cocktail, REGEN-COV, as a passive vaccine to prevent COVID-19 in people at high risk of infection from household exposure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
British scientists suggested last week that the U.K. variant may be approximately 30% more lethal than the most common strain that came out of China. But they’re not completely sure of this yet.
Moderna announced it has started development on a booster to its COVID-19 vaccine, which the company hopes will work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
PRESS RELEASES